Dr. Guru Sonpavde, Genitourinary Oncology Director at the AdventHealth Cancer Institute and the Christopher K. Glanz Chair for Bladder Cancer Research, recommends the following abstracts being presented at this year's ESMO Congress, held September 13 through 17, 2024, in Barcelona.

Friday, September 13, 2024
4:00 PM–5:30 PM CEST; Proffered Paper Session 1

GU Tumours, Non-Prostate

1959O BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC). D Ye

• This appears to be a highly promising antibody–drug conjugate binding both EGFR and HER3 for the therapy of advanced urothelial carcinoma.

Sunday, September 15, 2024
4:30 PM–5:50 PM CEST; Presidential Symposium II

Practice-Changing Trials

LBA5 A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA). TB Powles

• This trial is highly likely to change practice. A press release has already reported improved event-free and overall survival for the combination of neoadjuvant plus adjuvant durvalumab with neoadjuvant cisplatin plus gemcitabine chemotherapy in the setting of radical cystectomy.

Monday, September 16, 2024
8:30 AM–10:00 AM CEST; Proffered Paper Session 2

GU Tumours, Non-Prostate

1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial. JB Jensen

• The prospective phase II trial data regarding the role for ctDNA to select muscle-invasive bladder cancer patients for adjuvant atezolizumab therapy are eagerly awaited.

ESMO 2024, blaaskanker, aanbevolen abstracten

---

• ESMO 2023: aanbevolen abstracten voor blaaskanker, nierkanker en urineleiderkanker

---

• ESMO 2022: aanbevolen abstracten gerelateerd aan blaaskanker en nierkanker door vooraanstaande oncologen.

---

• Regulier - blaaskanker: actuele ontwikkelingen en belangrijke studies binnen de reguliere oncologie: een overzicht